Biotech Acquisition Co (Biotech Acquisition Co) Cash-to-Debt : 0.04 (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Biotech Acquisition Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Biotech Acquisition Co's cash to debt ratio for the quarter that ended in Sep. 2022 was 0.04.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Biotech Acquisition Co couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2022.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Biotech Acquisition Co's Cash-to-Debt or its related term are showing as below:

BIOT's Cash-to-Debt is not ranked ^*
in the Diversified Financial Services industry.
Industry Median: 5.385
* Ranked among companies with meaningful Cash-to-Debt only.

Biotech Acquisition Co Cash-to-Debt Historical Data

The historical data trend for Biotech Acquisition Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Biotech Acquisition Co Cash-to-Debt Chart

Biotech Acquisition Co Annual Data

Trend

Dec20

Dec21

Cash-to-Debt

No Debt

Biotech Acquisition Co Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Cash-to-Debt	Get a 7-Day Free Trial				No Debt	No Debt	0.90	0.01	0.04

Competitive Comparison of Biotech Acquisition Co's Cash-to-Debt

For the Shell Companies subindustry, Biotech Acquisition Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biotech Acquisition Co's Cash-to-Debt Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Biotech Acquisition Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Biotech Acquisition Co's Cash-to-Debt falls into.

Biotech Acquisition Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Biotech Acquisition Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Biotech Acquisition Co had no debt ⁽¹⁾.

Biotech Acquisition Co's Cash to Debt Ratio for the quarter that ended in Sep. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.013	/	(0.305	+	0)
	=	0.04

Biotech Acquisition Co (NAS:BIOT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Biotech Acquisition Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Biotech Acquisition Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotech Acquisition Co (Biotech Acquisition Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Biotech Acquisition Co (NAS:BIOT) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

545 West 25th Street, 20th Floor, New York, NY, USA, 10001

Website

Biotech Acquisition Co is a blank check company.

Executives

Albert F Hummel	director, officer: Chief Investment Officer	PO BOX 3407, RANCHO SANTA FE CA 92067
Biotech Sponsor Llc	10 percent owner	545 W. 25TH ST., 20TH FLOOR, NEW YORK NY 10001
Bruno Montanari	director	545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Ivan Jarry	officer: Chief Operating Officer	545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Paul Bernard	director	545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Aaron Kim	director	545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Michael Schleifer	director, 10 percent owner, officer: Chief Executive Officer	545 WEST 25TH STREET 20TH FLOOR, NEW YORK NY 10001
Thomas Fratacci	officer: CFO & Treasurer	545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001